Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1 β-L-ribofuranosyl)-1H-benzimidazole
The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
1. A crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, wherein the crystalline form is a hydrochloride monohydrate salt, and wherein the crystalline form has unit cell parameters a=22.25 Å, b=22.25 Å, c=8.016 Å, and P4 2 2 1 2 space group (recorded at 293 K).
2. A crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, wherein the crystalline form is a hydrochloride monohydrate salt, and wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1° and 7.996±0.1°2-theta.
3. The crystalline form of claim 2 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1°, 7.996±0.1°, 8.921±0.1°, 16.881±0.1°, and 22.613±0.1°2-theta.
4. The crystalline form of claim 2 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1°, 7.996±0.1°, 8.921±0.1°, 14.375±0.1°, 16.881±0.1°, 19.857±0.1°, 20.997±0.1°, 22.613±0.1°, 22.842±0.1°, and 25.298±0.1°2-theta.
5. The crystalline form of claim 2 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1°, 7.996±0.1°, 8.921±0.1°, 11.280±0.1°, 11.734±0.1°, 14.375±0.1°, 16.881±0.1°, 19.857±0.1°, 20.997±0.1°, 21.506±0.1°, 22.613±0.1°, 22.842±0.1°, 23.989±0.1°, 24.948±0.1°, and 25.298±0.1°2-theta.
6. The crystalline form of claim 2 , wherein the X-ray powder diffraction pattern is collected using a TTK450 chamber.
7. The crystalline form of claim 2 , wherein the X-ray powder diffraction pattern is collected using copper K-alpha radiation.
8. The crystalline form of claim 7 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1°, 7.996±0.1°, 8.921±0.1°, 11.280±0.1°, 11.734±0.1°, 14.375±0.1°, 16.881±0.1°, 19.857±0.1°, 20.997±0.1°, 21.506±0.1°, 22.613±0.1°, 22.842±0.1°, 23.989±0.1°, 24.948±0.1°, and 25.298±0.1°2-theta.
9. The crystalline form of claim 2 , prepared by the steps of:
(i) providing a solution of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole in aqueous hydrochloric acid,
(ii) maintaining the mixture at room temperature, and
(iii) evaporating the aqueous hydrochloric acid to provide a crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole hydrochloride monohydrate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1° and 7.996±0.1°2-theta.
10. A pharmaceutical composition comprising the crystalline form of claim 2 and at least one pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 in the form of a powder, tablet, capsule, or suspension.
12. A method for treatment or prophylaxis of a herpes, hepatitis B, or hepatitis C viral infection in a patient in need thereof, comprising administering to said patient an effective anti-viral amount of the crystalline form of claim 2 .
13. A method of making the crystalline form of claim 2 , comprising the steps of:
(i) providing a solution of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole in aqueous hydrochloric acid,
(ii) maintaining the mixture at room temperature, and
(iii) evaporating the aqueous hydrochloric acid to provide a crystalline form of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole hydrochloride monohydrate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.619±0.1° and 7.996±0.1°2-theta.